mRNA Manufacturing and Synthesis Services Market Top Companies Study - Celonic AG, Corden Pharma GmbH, Lonza Group AG, Rentschler Biopharma, Laboratorios Farmacéuticos Rovi

mRNA Manufacturing and Synthesis Services Market worth $22.6 Billion by 2031- Growing Beyond COVID-19 Application

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global mRNA Manufacturing and Synthesis Services Market- By. Type of Industry (Therapeutics/Vaccine Developers, CDMO Organizations, Custom Synthesis/Other Service Providers) By Scale of Operation (Research / Preclinical, Clinical, Commercial) and By Application (Infectious Disease Vaccines, Other Vaccines, Therapeutics and Others)"

Get Free Access to Demo Report, Excel Pivot and ToC: www.insightaceanalytic.com/request-sample/1185

According to the most recent study, the global market for mRNA manufacturing and synthesis services is expected to grow at a compound annual growth rate (CAGR) of -3.4% from US$ 53,278.8 million in 2021 to US$ 22,634.5 million in 2031 during the forecast period (2022-2031). The success of the COVID-19 vaccinations in 2021 caused the market to expand rapidly, which in turn led to a huge need for a steady supply of vaccines. Nevertheless, the market is expected to contract at a growth rate of -42.0% in 2022. Aside with COVID-19 applications, the mRNA Synthesis and Manufacturing Services market is still in its infancy and presents enormous growth and penetration potential over the course of the projection period. There is a robust pipeline of mRNA vaccines for diseases like Lyme disease, influenza, malaria, hemorrhagic fever, genital herpes, and others that should be introduced over the predicted period.

With a market share of 33.4% in 2021, Asia Pacific led the industry due to the high demand for the COVID-19 vaccination. Some of the factors anticipated to support the market growth of mRNA Manufacturing and Synthesis services over the forecast period include the potential for low-cost manufacturing, improved immunogenicity, higher effectiveness of mRNA vaccine compared to other vaccine technologies, and ongoing R&D innovations & developments in mRNA Manufacturing and Synthesis services.

Additionally, the market for mRNA Manufacturing and Synthesis services is expected to rise during the forecast period because to the increasing number of clinical trials for cancer medicines, the growing burden of infectious diseases, and innovative developments by pharmaceutical CDMO businesses. However, one of the biggest challenges facing the manufacturers is preserving the high stability and purity of the mRNA products.

Due to strong demand, growing public awareness about mRNA vaccines, and rising government funding in research and development to treat infectious diseases, the North American and Asia Pacific regions account for most of the this market's revenue.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

The key CDMO organizations operating in the mRNA Manufacturing and Synthesis services market are eTheRNA (Etherna Immunotherapies), Celonic AG, Corden Pharma GmbH, Lonza Group AG, Rentschler Biopharma, Laboratorios Farmacéuticos Rovi, S.A., Samsung Biologics, Thermo Fisher Scientific, Sartorius (BIA Separations) among others
Noticeably Custom Synthesis/Other Service Providers are Eurogentec, Aldevron, bioSYNTHESIS, TriLink BioTechnologies, Biomay, Jena Biosciences, APExBIO, CELLSCRIPT, New England Biolabs, Kernal Biologics, Cytiva, among others
Foremost leaders in Therapeutics and Vaccine Developers are CureVac, Moderna, BioNTech (Pfizer), Translate Bio, Ethris (AstraZeneca), Silence Therapeutics, Tiba Biotechnology, In-Cell-Art, Anima Biotech, H3 Biomedicine Inc., Arcturus Therapeutics, eFFECTOR Therapeutics, Inc., Ziphius Therapeutics NV, Ionis Pharmaceuticals, Inc., Skyhawk Therapeutics, Inc., Stemirna Therapeutics Co., Ltd., RNAimmune (Sirnaomics), miRagen Therapeutics, Inc., Strand Therapeutics Inc., Nutcracker Therapeutics. Accurna Inc., Amgen Inc., Argos Therapeutics Inc., Arrowhead Pharmaceuticals. Athersys, Biocad, Boehringer Ingelheim, Cansinobio. Cartesian Therapeutics Inc, Chimeron Bio, Crispr Therapeutics Inc., Daiichi Sankyo, Eli Lilly And Co., Elixirgen Therapeutics Inc., Genentech (Subsidiary Of Roche), Greenlight Biosciences Inc., HDT Bio Corp., Intellia Therapeutics, Maxcyte Inc., Merck Kgaa, Mercurna, Novartis, Phion Therapeutics, Poseida Therapeutics Inc., Recode Therapeutics, Regulus Therapeutics, Sangamo Therapeutics Inc, Sanofi, Sarepta Therapeutics, Shanghai Bendao Gene Technology Co., Ltd., Vertex Pharmaceutical.

Key manufacturers in this field focus on offering high-quality services to clients. Also, strategies such as collaborations, partnerships, mergers, and acquisitions help boost their manufacturing capacities. Some of the key developments in the global market are as follow:
• In Feb 2022, Moderna launched early-stage clinical trials of an HIV mRNA vaccine. Earlier, IAVI and Moderna announced that the first doses have been administered in a clinical trial of experimental HIV vaccine antigens. The Phase I trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development.
• In Feb 2022, eTheRNA immunotherapies NV announced a strategic partnership with Merck KGaA. The partnership investigates the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany. With this collaboration, eTheRNA and Merck KGaA, Darmstadt, Germany, assess the feasibility of using eTheRNA's mRNA and LNP technologies to develop therapeutic vaccination approaches in disease models.
• In Oct 2021, Vertex Pharmaceuticals Inc. announced a partnership with a California startup to develop therapies for two genetic diseases. Vertex has developed cystic fibrosis therapies and is working with other partners on CRISPR-Cas9 systems and messenger RNA, or mRNA, therapies with Moderna Inc.

Unlock Your GTM Strategy: www.insightaceanalytic.com/customisation/1185

Market Segments
mRNA Manufacturing and Synthesis Services Market Revenue by Application (Value US$ Mn) Forecast 2022-2031
• Therapeutics and Vaccine Developers
• CDMO Organizations
• Custom Synthesis/Other Service Providers

mRNA Manufacturing and Synthesis Services Market Revenue by Application (Value US$ Mn) Forecast 2022-2031
• Infectious Disease Vaccines
• Other Vaccines
• Therapeutics and Others

mRNA Manufacturing and Synthesis Services Market Revenue by Scale of Operation (Value US$ Mn) Forecast 2022-2031
• Research / Preclinical
• Clinical
• Commercial

mRNA Manufacturing and Synthesis Services Market Revenue by Product (Value US$ Mn) Forecast 2022-2031
• API
• Drug Products

North America mRNA Manufacturing and Synthesis Services Market Revenue (US$ Million) By Country, 2022 To 2031
• U.S.
• Canada
Europe mRNA Manufacturing and Synthesis Services Market Revenue (US$ Million) By Country, 2022 To 2031
• Germany
• France
• Spain
• Italy
• Russia
• Rest of Europe
Asia Pacific mRNA Manufacturing and Synthesis Services Market Revenue (US$ Million) By Country, 2022 To 2031
• India
• Australia
• South Korea
• China
• Japan
• Rest of Asia Pacific
Latin America mRNA Manufacturing and Synthesis Services Market Revenue (US$ Million) By Country, 2022 To 2031
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa mRNA Manufacturing and Synthesis Services Market Revenue (US$ Million) By Country, 2022 To 2031
• South Africa
• GCC Countries
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ www.insightaceanalytic.com/buy-report/1185

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.